reports
Cosmos Yatirim Ortakligi AS: 1 director
A director at Cosmos Yatirim Ortakligi AS sold 1,890,600 shares at 194.300TRY and the significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
Wasion Holdings Limited: 1 director
A director at Wasion Holdings Limited sold 50,000 shares at 30.760HKD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Wanguo Gold Group Ltd: 1 director
A director at Wanguo Gold Group Ltd bought 20,000,000 shares at 12.060HKD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financia...
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading and every-three-week maintenance dose of ficerafusp alfa Corporate call to discuss financial results and business updates on Monday, March 30, 2026 at 8:30 a.m. ET BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX) today announced financial results...
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% ...
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported independent clinical validation of its Phase 2 SkinJect® dataset from Dr. Babar ...
Palvella Therapeutics Announces Scientific Publication in Journal of V...
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial design and treatment approaches Manuscript emphasizes the importance of early therapeutic intervention in children to help reduce the risk of more serious complications over time Review supports the scientific rationale of QTORIN™ 3.9% rapamycin anhy...
Bombardier Announces Extension of Consent Solicitation with Respect to...
Bombardier Announces Extension of Consent Solicitation with Respect to its 7.35% Debentures due 2026 MONTRÉAL, March 30, 2026 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has extended the expiration date of its previously announced consent solicitation (the “Canadian Consent Solicitation”) in respect of its 7.35% Debentures due 2026 (the “Canadian Notes”). The Consent Deadline (as defined in the Consent Solicitation Statement referred to below) for the Canadian Notes has been extended to 5:00 p.m., Eastern time, on April 10, 2026 (the “Extended Consent Deadli...
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spina...
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patientsHigh Dose SPINRAZA will be available in the United States in the coming weeks and is also approved in the European Union, Switzerland and Japan CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) today announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised o...
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangre...
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab in pyoderma gangrenosum (PG) were featured in an oral presentation during the Late-Breaking Research abstract session at the 2026 American Academy of Dermatology (AAD) Annual Meeti...
Anavex Life Sciences Provides Comprehensive Regulatory Update
Anavex Life Sciences Provides Comprehensive Regulatory Update Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional data submitted to the U.S. FDA with the objective to discuss potential pathways towards a New Drug Application (NDA) for the treatment of early Alzheimer’s disease Additionally, Anavex has engaged in discussions with EU regulators regarding blarcamesine for Parkinson’s disease and rare diseases, including Rett syndrome NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life ...
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with L...
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 - Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically meaningful improvements in ambulation and pulmonary function - Based on ongoing discussions with the FDA, BridgeBio anticipates approval with a U.S. launch anticipated in late 2026/early 2027 - If approved, BBP-418 has the potential to become the first and only therapy for individuals living with LGMD2I/R9 and may ...
Bombardier annonce la prorogation de la sollicitation de consentements...
Bombardier annonce la prorogation de la sollicitation de consentements à l’égard de ses débentures 7,35 % échéant en 2026 MONTRÉAL, 30 mars 2026 (GLOBE NEWSWIRE) -- Bombardier Inc. (« Bombardier ») a annoncé aujourd’hui le report de la date d’expiration de sa sollicitation de consentements précédemment annoncée (la « sollicitation des consentements canadiens ») à l’égard de ses débentures 7,35 % échéant en 2026 (les « billets canadiens »). La date limite de remise des consentements (au sens défini dans la déclaration de sollicitation de consentements dont il est fait mention ci-dessous) à...
BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceu...
BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder Commercial agreement serves as high-profile third party validation of BullFrog AI’s proprietary capabilities Agreement utilizes BullFrog AI’s end-to-end analytical AI platform to accelerate drug discovery and development program GAITHERSBURG, Md., March 30, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology company using artificial intelligence (“AI”) and machine...
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentat...
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 FLORHAM PARK, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced that the Company will have a poster presentation at the , taking place on April 17 through 22, 2026 in San Diego, California. Presentation Details: Title: Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or...
Bitfarms to Participate in Jefferies Fireside Chat
Bitfarms to Participate in Jefferies Fireside Chat TORONTO, Ontario and NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX: BITF), a North American digital infrastructure and energy company, will participate in a fireside chat at the Jefferies Virtual Power x Data Center Conference. Jefferies Virtual Fireside ChatDate: Tuesday, March 31, 2026Time: 10:15 AM EasternPresenters: CEO, Ben Gagnon and CFO Jonathan Mir About Bitfarms Ltd.Bitfarms is a North American digital infrastructure and energy company that develops and owns data centers and energy infrastructure for h...
NEURONES : Déclaration des transactions sur actions propres (période d...
NEURONES : Déclaration des transactions sur actions propres (période du 23 au 27 mars 2026) Nanterre, le 30 mars 2026 Déclaration des transactions sur actions propres(période du 23 au 27 mars 2026) Dans le cadre du programme de rachat d’actions propres autorisé par l’Assemblée Générale du 5 juin 2025 et confié au CIC, NEURONES a procédé, entre le 23 et le 27 mars 2026, aux achats suivants (code ISIN FR0004050250) : JourVolume total journalier(en nombre d'actions)Prix pondéré moyen(journalier unitaire)23/03/202646 39234,13 €24/03/202642 99333,47 €25/03/202611 66534,58 €26/03/20267 16634,2...
NEURONES: Declaration of transactions on treasury shares (March 23 to ...
NEURONES: Declaration of transactions on treasury shares (March 23 to 27, 2026) Nanterre, March 30, 2026 Declaration of transactions on treasury shares(period from 23 to 27 March 2026) As part of the share buyback program authorized by the General Meeting of June 5, 2025 and entrusted to CIC, NEURONES made the following purchases between March 23 and 27, 2026 (ISIN code FR0004050250): DayTotal daily volume(in number of shares)Weighted average price(unit daily)03/23/202646,39234.13 €03/24/202642,99333.47 €03/25/202611,66534.58 €03/26/20267,16634.26 €03/27/20266,80534.43 €Total115,021 As o...
Alterity Therapeutics Receives Positive FDA Feedback Following Type C ...
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program Alignment reached on key elements of ATH434 Phase 3 development program MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 developme...
Limak Dogu Anadolu Cimento: 1 director
A director at Limak Dogu Anadolu Cimento bought 764,751 shares at 33.225TRY and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Chinasoft International Limited: 1 director
A director at Chinasoft International Limited bought 2,000,000 shares at 3.404HKD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.